saxenda semaglutide Obesity saxenda semaglutide Saxenda® Class Action

This week's new product roundup features GLP-1-friendly innovation from Todo and Shaklee, the debut of a 'kratom brewski' and seasonal limited releases from Juni, Q Mixers and Wynk.

The FDA has issued warnings about unapproved GLP-1 drugs circulating online - counterfeit, compounded, or mislabeled as research use only. When access to legitimate GLP-1 clinical trials is limited - by geography, logistics, or site capacity - progress slows

Batch identification supports laboratory traceability, quality management and accurate research documentation

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Original makers Novo Nordisk not dropping price despite competition, says it is driven by patient trust, not patents